Good morning. Elizabeth Cooney here at STAT HQ in Boston, pinch-hitting for Ed Silverman, who would no doubt remind you we have survived until the middle of the week. Not sure that resonates with Ed and others at the swirling conference called J.P. Morgan in San Francisco, but that, too, shall pass. We have lots of news to share in the meantime.

Democrats heaped criticism on pharma during Tuesday’s debate, highlighting a long list of policies they say will help lower high drug prices, STAT reports. Sen. Elizabeth Warren (D-Mass.), in particular, doubled down on a pledge to lower drug prices on her first day as president, using executive action to make it easier for generic drug makers to move in on brand-name drugs that were created using federally funded research.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy